Native by design
We begin with antibodies in their intended species format—creating a direct path from discovery to a potential medicine.
Next-generation animal therapeutics
Species-native
antibodies.
Building precision antibody medicines for the animals that share our lives.
Species-native by design
Multi-species platform
Built in Germany
Our purpose
01
Better medicines for the animals beside us.
Companion animals face many of the same complex diseases we do, but their treatment options remain limited.
AnsoThera is creating a new generation of targeted biologics designed from the outset for the species they will serve.
Our approach
02
Native from
the first step.
A proprietary transgenic discovery platform built to access complete, species-native antibody repertoires.
One platform, multiple species
A scalable foundation for canine, feline, equine, and other companion-animal antibody programs.
Built for translation
Focused on meaningful targets, disciplined development, and therapeutics with real clinical potential.
An emerging animal-health company
We are building the discovery engine for a new class of companion-animal medicines.
AnsoThera is advancing its platform and first therapeutic programs while exploring select strategic and investment partnerships.
Leadership
03
Deep science.
Built to translate.
A team spanning B-cell biology, antibody and genome engineering, transgenic model design, biomanufacturing, intellectual property, and company building.
Co-Founder · Antibody genetics
Hans-Martin Jäck
Senior Professor of Molecular Immunology at FAU Erlangen–Nürnberg and founder of TRIANNI, with decades of expertise in B-cell biology, transgenic models, and monoclonal-antibody discovery.
Co-Founder · Discovery platforms
Nigel Killeen
Immunologist and former UCSF faculty member who played a pivotal role as TRIANNI CSO in developing and validating its antibody-discovery platform.
Co-Founder · Biomanufacturing
Donald Gerson
Bioprocessing leader with executive experience across Celltrion, Wyeth-Lederle, and Acambis, spanning vaccines, biologics, and global facilities.
Co-Founder · Platform development
Sebastian Schulz
Antibody researcher with more than a decade in B-cell biology, monoclonal-antibody discovery and mouse platform development.
Co-Founder · IP strategy
Stefan Bianchin
Attorney-at-law and European Patent Attorney combining technical and legal training with international patent, licensing, and IP-strategy experience.
Co-Founder · Bioprocess engineering
Jonas Gerson
Chemical engineer with two decades in bioprocessing and senior CDMO engineering roles, focused on scale-up and large-scale manufacturing.
Senior Business Adviser
Oscar Mendoza
Brings more than 30 years of experience in the global animal-health industry, advising AnsoThera on strategic partnerships, international business development, and sustainable growth.
Let’s talk
Building what comes next in animal health.
We welcome conversations with investors, animal-health innovators, researchers, and future partners.
contact@ansothera.com AnsoThera GmbHDamaschkestraße 63
D-91088 Bubenreuth · Germany